<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034279</url>
  </required_header>
  <id_info>
    <org_study_id>INFECIR 2</org_study_id>
    <secondary_id>2013-002416-27</secondary_id>
    <nct_id>NCT02034279</nct_id>
  </id_info>
  <brief_title>The INFECIR-2 Albumin Prevention Study</brief_title>
  <acronym>INFECIR2</acronym>
  <official_title>Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EASL - CLIF Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EASL - CLIF Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether albumin administration improves short-term
      survival in patients with advanced cirrhosis and bacterial infections other than Spontaneous
      Bacterial Peritonitis (SBP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate if IV albumin administration improves short-term
      survival in patients with advanced cirrhosis (serum creatinine ≥ 1.2 mg/dl, serum sodium ≤
      130 mEq/l -milliequivalents per liter- and/or serum bilirubin ≥4 mg/dl) and bacterial
      infections other than spontaneous bacterial peritonitis (urinary infection, pneumonia,
      spontaneous or secondary bacteremia, skin/soft tissue infection, acute cholangitis or
      suspected bacterial infection).

      Primary goals of the study:

      • Effect of albumin administration on hospital survival

      Secondary goals of the study:

        -  Effect of albumin administration on 28-day and 90-day survival.

        -  Effect of albumin administration on the incidence of renal dysfunction, AKI, type-1 and
           2 Hepatorenal Syndrome (HRS) during hospitalization.

        -  Effect of albumin on circulatory function estimated by changes in plasma levels of renin
           and noradrenaline and in serum levels of lactate among infection diagnosis, day 3 and
           infection resolution.

        -  Effect of albumin on serum levels of interleukin-6 (IL-6), tumor necrosis factor alpha
           (TNF-alpha) and nitric oxide (NOX) and on plasma levels of von Willebrand factor
           (vWF:Ag) at diagnosis and resolution of infection.

        -  Effect of albumin on blood leukocyte count and serum C-reactive protein levels (CRP)
           during infection.

        -  Effect of albumin on the development of other individual organ failures (renal, liver,
           cerebral, circulatory, coagulation and respiratory), acute-on-chronic liver failure
           (ACLF type 1, 2 and 3 according to the Canonic Study), CLIF-SOFA score, CLIF-Consortium
           score, Child-Pugh score and MELD score during hospitalization.

        -  Evaluation of predictive factors of HRS and ACLF development in non-SBP infections.

        -  Samples (blood, plasma, serum and urine) will be obtained and stored for genomic,
           proteomic and standard biochemical investigations in future ancillary studies related to
           the aim of the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment rate and expiration of the study drug
  </why_stopped>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">February 10, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>hospitalization</time_frame>
    <description>Hospital survival will be the primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>28-d and 90-day survival</time_frame>
    <description>Percentage of subjects within each arm that survived at these time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>hospitalization (expected average 2 weeks)</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulatory dysfunction</measure>
    <time_frame>day 3 and day of infection resolution</time_frame>
    <description>plasma concentration of hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation and endothelial function</measure>
    <time_frame>day of infection resolution</time_frame>
    <description>Plasma concentration of cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subsequent organ failure</measure>
    <time_frame>hospitalization (expected average 2 weeks)</time_frame>
    <description>number of organ failures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Advanced Chronic Liver Disease</condition>
  <condition>Urinary Infection</condition>
  <condition>Pneumonia</condition>
  <condition>Cholangitis</condition>
  <condition>Other Bacterial Diseases</condition>
  <arm_group>
    <arm_group_label>Intravenous infusion of albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm will receive intravenous albumin on days 1 and 3 plus antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No albumin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Intravenous infusion of 20% albumin</description>
    <arm_group_label>Intravenous infusion of albumin</arm_group_label>
    <other_name>Albutein 20 by Grifols</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhotic patients with age ≥18 years

          -  Diagnosis of urinary infection, pneumonia, spontaneous or secondary bacteremia,
             skin/soft tissue infection, acute cholangitis or suspected bacterial infection at
             hospital admission or during hospitalization

          -  Patients with uncomplicated urinary infections or suspected bacterial infection will
             require the presence of signs of systemic inflammation: at least 1 diagnostic
             criterion of systemic inflammatory response syndrome (SIRS) and serum CRP levels ≥1
             mg/dl (10 mg/L). This criterion will not be required for the rest of infections

          -  Analytical data of renal and/or liver dysfunction (serum creatinine ≥ 1.2 mg/dl, serum
             sodium ≤ 130 mEq/l, serum bilirubin ≥4 mg/dl). Patients with pneumonia or documented
             bacteremia (positive blood cultures) will require the presence of at least 1 of these
             analytical criteria to be included in the study. Patients with urinary infection,
             skin/soft tissue infection, acute cholangitis or suspected bacterial infection will
             require 2 or more criteria for inclusion

        Exclusion Criteria:

          -  &gt; 72h after infection diagnosis

          -  Pregnancy

          -  Acute or subacute liver failure without underlying cirrhosis

          -  Septic shock

          -  Severe acute respiratory distress syndrome (Pa02/Fi02 ≤ 100)

          -  Active or recent variceal bleeding unless controlled for &gt; 48h

          -  Ongoing type-1 HRS (past IAC criterion: serum creatinine ≥ 2.5 mg/dl)

          -  Type-3 ACLF (defined according to the Canonic Study criteria)

          -  Hemodialysis or other renal replacement therapy

          -  Evidence of current malignancy (except for hepatocellular carcinoma within Milan
             criteria or non-melanocytic skin cancer)

          -  Moderate or severe chronic heart (NYHA class II, III or IV) or pulmonary disease (GOLD
             IV)

          -  Severe psychiatric disorders

          -  Previous liver transplantation

          -  HIV infection (except for patients under antiretroviral therapy with undetectable
             viral load, CD4&gt;200/mm3 and no history of opportunistic infections diagnostic of AIDS)

          -  Contraindications to albumin (allergy, signs of pulmonary edema)

          -  Albumin administration (≥ 80g) in the last 2 days

          -  Spontaneous bacterial peritonitis coinfection

          -  Use of any investigational drug within 90 days prior to randomization

          -  Refusal to participate

          -  Patients who cannot provide prior informed consent and when there is documented
             evidence that the patient has no legal surrogate decision maker and it appears
             unlikely that the patient will regain consciousness or sufficient ability to provide
             delayed informed consent

          -  Physician and team not committed to intensive care if needed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Gustot</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick Nevens</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals KU, Leuven, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faouzi Saliba</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Paul Brousse, Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Durand</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon, Clichy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Dollinger</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm, Heidelberg and Tübingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Zeuzem</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Frankfurt, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Gerbes</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonel Trebicka</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Bonn, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henning Gronbaeck</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fin Stolze Larsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Willy Haukeland</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea de Gottardi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aide McCormick</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College of Dublin, Ireland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajiv Jalan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Domenicali</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Angeli</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlo Alessandria</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Giovanni Battista Hospital, University of Turin, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Salerno</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico IRCCS San Donato, University of Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agustin Albillos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ramon y Cajal, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Vargas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Fernandez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>German Soriano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Creu i Sant Pau, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Bañares</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gregorio Marañon, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Luis Montero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Reina Sofia, Cordoba, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuela Merli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minneke Coenraad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rudolf Stauber</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Vogel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Hospital Innsbrück</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.clifresearch.com/infecir2/Home.aspx</url>
    <description>Web page of the INFECIR-2 RCT</description>
  </link>
  <reference>
    <citation>Guevara M, Terra C, Nazar A, Solà E, Fernández J, Pavesi M, Arroyo V, Ginès P. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol. 2012 Oct;57(4):759-65. doi: 10.1016/j.jhep.2012.06.013. Epub 2012 Jun 23.</citation>
    <PMID>22732511</PMID>
  </reference>
  <reference>
    <citation>Thévenot T, Bureau C, Oberti F, Anty R, Louvet A, Plessier A, Rudler M, Heurgué-Berlot A, Rosa I, Talbodec N, Dao T, Ozenne V, Carbonell N, Causse X, Goria O, Minello A, De Ledinghen V, Amathieu R, Barraud H, Nguyen-Khac E, Becker C, Paupard T, Botta-Fridlung D, Abdelli N, Guillemot F, Monnet E, Di Martino V. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol. 2015 Apr;62(4):822-30. doi: 10.1016/j.jhep.2014.11.017. Epub 2014 Nov 21.</citation>
    <PMID>25463545</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

